Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the united states Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the united states

Circulation: Heart Failure

Volumn 6, Issue 1, 2013, Pages

  Acker, Michael A ^a,b   Pagani, Francis D ^c   Stough, Wendy Gattis ^d   Mann, Douglas L ^a   Jessup, Mariell ^e   Kormos, Robert ^f   Slaughter, Mark S ^g   Baldwin, Timothy ^h   Stevenson, Lynne ^b   Aaronson, Keith D ⁱ   Miller, Leslie ^j   Naftel, David ^k   Yancy, Clyde ^l   Rogers, Joseph ^m   Teuteberg, Jeffrey ⁿ   Starling, Randall C ^o   Griffith, Bartley ^p   Boyce, Steven ^q   Westaby, Stephen ^r   Blume, Elizabeth ^s   Wearden, Peter ^t   Higgins, Robert ^u   Mack, Michael ^a,u   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c CAMPBELL UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f University of Louisville School of Medicine   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF SOUTH FLORIDA   (United States)

^j Kentucky   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁿ LERNER RESEARCH INSTITUTE   (United States)

^o UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^p WASHINGTON HOSPITAL CENTER   (United States)

^q JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^r BOSTON CHILDREN S HOSPITAL   (United States)

^s CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^t OHIO STATE UNIVERSITY   (United States)

^u MEDICAL CITY DALLAS HOSPITAL   (United States)

more..

Author keywords

AHA Scientific Statements; Heart failure; Heart assist device

Indexed keywords

ARTICLE; ASSISTED CIRCULATION; CARDIOLOGY; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE SEVERITY; EUROPE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEART FAILURE; HUMAN; HUMAN NEEDS; JAPAN; MARKETING; MEDICAL DECISION MAKING; MEDICAL DEVICE; MEDICAL SOCIETY; MEDICARE; PATIENT SAFETY; PEDIATRICS; POSTMARKETING SURVEILLANCE; PRE MARKETING; PRIORITY JOURNAL; RELIABILITY; TREATMENT OUTCOME; UNITED STATES; VENTRICULAR ASSIST DEVICE;

AMERICAN HEART ASSOCIATION; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSTHESIS DESIGN; REGISTRIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84873695215     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/HHF.0b013e318279f6b5     Document Type: Article

References (37)

1. Challoner DR, Vodra WW. Medical devices and health-creating a new regulatory framework for moderate-risk devices. N Engl J Med. 2011;365:977-9.
2. Curfman GD, Redberg RF. Medical devices-balancing regulation and innovation. N Engl J Med. 2011;365:975-7.
3. Hauser RG. Here we go again-failure of postmarketing device surveillance. N Engl J Med. 2012;366:873-5.
4. Kramer DB, Xu S, Kesselheim AS. Regulation of medical devices in the United States and European Union. N Engl J Med. 2012;366:848-55.
5. Resnic FS, Normand SL. Postmarketing surveillance of medical devices-filling in the gaps. N Engl J Med. 2012;366: 875-7.
6. Hearing: Regulatory reform series #5. FDA medical device regulation: Impact on American patients, innovation and jobs. Available at: Http://www.fda. gov/newsevents/testimony/ucm263491.htm. Accessed October 15, 2011.
7. Institute of Medicine. Medical devices and the public's health: The FDA 510(k) clearance process at 35 years. Washington, DC: National Academies Press, 2011.
8. Kirklin JK, Naftel DC, Kormos RL, et al. Third INTERMACS annual report: The evolution of destination therapy in the United States. J Heart Lung Transplant. 2011;30:115-23.
9. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-51.
10. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435-43.
11. Parides MK, Moskowitz AJ, Ascheim DD, Rose EA, Gelijns AC. Progress versus precision: Challenges in clinical trial design for left ventricular assist devices. Ann Thorac Surg. 2006;82:1140-6.
12. Chen E, Sapirstein W, Ahn C, Swain J, Zuckerman B. FDA perspective on clinical trial design for cardiovascular devices. Ann Thorac Surg. 2006;82:773-5.
13. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med. 2007;357:885-96.
14. Aaronson KD, Patel H, Pagani FD. Patient selection for left ventricular assist device therapy. Ann Thorac Surg. 2003;75(Suppl):29-35.
15. Boyle AJ, Ascheim DD, Russo MJ, et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant. 2011;30:402-7.
16. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: Implications for patient selection. Circulation. 2007;116:497-505.
17. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: The current picture. J Heart Lung Transplant. 2009;28:535-41.
18. Aaronson KD, Slaughter MS, Miller LW, et al, for the HeartWare Ventricular Assist Device (HVAD) Bridge to Transplant ADVANCE Trial Investigators. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation. 2012;125:3191-200.
19. Kirklin JK, Naftel DC, Kormos RL, et al. The frourth INTERMACS annual report: 4,000 implants and counting. J Heart Lung Transplant. 2012;31:117-26.
20. Whellan DJ, Nigam A, Arnold M, et al. Benefit of exercise therapy for systolic heart failure in relation to disease severity and etiology: Findings from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training study. Am Heart J. 2011;162:1003-10.
21. Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol. 2010;55:1826-34.
22. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539-49.
23. Jarcho JA. Resynchronizing ventricular contraction in heart failure. N Engl J Med. 2005;352:1594-7.
24. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-38.
25. Kirklin JK, Mehra MR. The dawn of the ISHLT Mechanical Assisted Circulatory Support (IMACS) registry: Fulfilling our mission. J Heart Lung Transplant. 2012;31:115-6.
26. Felker GM, Rogers JG. Same bridge, new destinations re-thinking paradigms for mechanical cardiac support in heart failure. J Am Coll Cardiol. 2006;47:930-2.
27. Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med. 2009;360:816-23.
28. Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009;302:2679-85.
29. Fraser AG, Daubert JC, Van de Werf F, et al. Clinical evaluation of cardiovascular devices: Principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology. Eur Heart J. 2011;32:1673-86.
30. Cingolani E, Stevens S, Shehata M, Diamond GA, Kaul S. Medical device regulatory reform: Insights from the Watchman left atrial appendage closure technology for stroke prophylaxis in atrial fibrillation. Arch Intern Med. 2011;171: 1670-2.
31. Sapirstein W, Chen E, Swain J, Zuckerman B. US FDA perspective on regulatory issues affecting circulatory assist devices. Expert Rev Med Devices. 2006;3:749-53.
32. Food and Drug Administration Center for Devices and Radiological Health. CDRH 2011. Draft guidance for industry and food and drug administration staff: Investigational device exemptions (IDE) for early feasibility medical device clinical studies, including certain first in human (FIH) studies. Available at: Http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ ucm277670.htm. Accessed August 9, 2012.
33. Food and Drug Administration Center for Devices and Radiological Health. CDRH 2012. Strategic priorities. Available at: Http://www.fda.gov/downloads/ aboutfda/centersoffices/officeofmedicalproductsandtobacco/cdrh/ cdrhvisionandmission/ucm288736.pdf. Accessed August 9, 2012.
34. Food and Drug Administration Center for Devices and Radiological Health. CDRH 2010. Japan-U.S. "Harmonization By Doing" HBD pilot program initiative, May 2010. Available at: Http://www.fda.gov/medicaldevices/ deviceregulationandguidance/internationalinformation/ucm053067.html. Accessed August 9, 2012.
35. Yamane T, Kyo S, Matsuda H, et al. Japanese guidance for ventricular assist devices/total artificial hearts. Artif Organs. 2010;34:699-702.
36. Lee J. Long-term mechanical circulatory support system reliability. Recommendation by the National Clinical Trial Initiative Subcommittee. ASAIO J. 2009;55:534-58.
37. Baldwin JT, Borovetz HS, Duncan BW, Gartner MJ, Jarvik RK, Weiss WJ. The National Heart, Lung, and Blood Institute pediatric circulatory support program: A summary of the 5-year experience. Circulation. 2011;123:1233-40.